Evil ... Thy name is Orville Redenbacher!!
Well-Known Member
- Joined
- Aug 18, 2005
- Messages
- 14,163
I've seen several articles on this subject recently. Its become this week's source of Internet outrage.
Mylan, over the course of several years, managed to corner the market on the EpiPens. They lack no competition and have raised prices on the pen from $57 in 2007 to $400.
Below is a solid synopsis of how this happened.
Mylan is former US-Based (W.Va-based) company now HQ'd in the Netherlands. Its CEO Heather Bresch is the daughter of U.S. Sen. Joe Manchin. She was also at the center of an academic scandal that brought down a president of WVU.
http://gizmodo.com/how-congress-the-fda-and-sarah-jessica-parker-helped-1785568792
Mylan, over the course of several years, managed to corner the market on the EpiPens. They lack no competition and have raised prices on the pen from $57 in 2007 to $400.
Below is a solid synopsis of how this happened.
Mylan is former US-Based (W.Va-based) company now HQ'd in the Netherlands. Its CEO Heather Bresch is the daughter of U.S. Sen. Joe Manchin. She was also at the center of an academic scandal that brought down a president of WVU.
Mylan acquired the EpiPen when it bought a group of medications from drug company Merck in 2007. At the time, the product only produced about $200 million in revenue. Today, according to Bloomberg, it makes about $1 billion per year for the formerly US-based company, now headquartered in the Netherlands after a corporate inversion last year.
The EpiPen is no longer covered by patent protection, but it still has no real competitors. Auvi-Q, the only thing that came close, was recalled for delivering faulty dosages almost a year ago. A competing drug company, Teva, didn’t win approval for its generic version of the EpiPen this year. Teva won’t try to win FDA approval again until at least 2017.
So what can a company like Mylan do to increase profits on an old product, like EpiPen, when it’s already captured 98 percent market share and has no real competitors?
One option is to increase prices. The second is to increase the size of the market by convincing regulators, like the FDA, that the product should be marketed directly to a wider swath of the population. Then, a company can swoop in with high-profile (albeit backdoor) endorsements, from people like Sarah Jessica Parker, to increase awareness about the conditions that EpiPen treats. Or, better still, why not push to have institutions like public schools incentivized under federal law to carry the product? Mylan has spent the past decade doing all of the above.
http://gizmodo.com/how-congress-the-fda-and-sarah-jessica-parker-helped-1785568792
Last edited: